Cancer Drugs

Cancer treatment in India could become more affordable for thousands of patients and their families after the government moved to restrict trade margins on a wider range of anti-cancer medicines. The latest government estimate puts the potential savings at approximately Rs 3,357.49 crore following price reductions reported by pharmaceutical companies.

The National Pharmaceutical Pricing Authority (NPPA) has capped trade margins at 30 per cent of the maximum retail price (MRP) for 137 non-scheduled anti-cancer medicines, including patented drugs. The revised prices are scheduled to come into effect on November 9, 2026.

The measure is intended to reduce the gap between the price at which medicines enter the distribution chain and the amount patients are ultimately asked to pay. Cancer medicines can be expensive, and the additional costs added at different stages of distribution can significantly increase the financial burden on households.

Price reductions reported across 120 medicines

According to information released by the Press Information Bureau on November 6, a total of 70 pharmaceutical companies had reported revised MRPs for 120 of the 137 medicines by November 4. These revisions covered 1,136 individual product variants, or stock-keeping units.

The government said the reported reductions in MRP range broadly from 20 per cent to 70 per cent, while the highest reduction recorded so far was 96.45 per cent. The actual reduction varies from one medicine and formulation to another; therefore, patients should check the revised price of their specific medicine rather than assume that every cancer drug will become cheaper by the same percentage.

The estimated savings of Rs 3,357.49 crore have been calculated by comparing the earlier prices with the revised prices and applying the difference to the sales volumes recorded between April 2025 and March 2026.

This calculation provides an estimate based on an earlier year's sales pattern. The amount should not be interpreted as money already saved by patients or as a guaranteed saving for every individual receiving cancer treatment. The actual benefit will depend on the medicines prescribed, their consumption and the prices charged after the new rules take effect.

What does the 30 per cent trade-margin cap mean?

Trade margin is the difference between the price at which a manufacturer supplies a medicine to a stockist or distributor and the maximum retail price at which it is sold to consumers. It represents the amount added along the supply chain before the medicine reaches the patient.

When these margins become excessive, the final MRP can rise substantially above the manufacturer's supply price. This can make essential treatment difficult to afford, particularly for patients who require medicines over an extended period.

Under the new arrangement, the trade margin on the identified non-scheduled anti-cancer medicines will be restricted to 30 per cent of the MRP, excluding applicable Goods and Services Tax. The government has used its powers under Paragraph 19 of the Drugs (Prices Control) Order, 2013, to introduce the measure in the public interest.

The policy is aimed at controlling excessive mark-ups rather than imposing one identical selling price on every cancer medicine. The revised MRP for each listed product will depend on the applicable price calculation and the information submitted by companies.

Why non-scheduled medicines are important

India already regulates the prices of medicines included in the National List of Essential Medicines through the price-control framework. Such scheduled medicines are subject to government-fixed ceiling prices.

However, a number of anti-cancer medicines fall outside the scheduled list. These non-scheduled products have been subject to a different monitoring framework, which generally restricts annual increases in their MRP. The new intervention extends stronger trade-margin control to 137 such anti-cancer medicines.

The inclusion of patented medicines is also significant because some newer cancer therapies can be costly. The policy covers a wider range of products and is intended to address the additional mark-ups that can arise between manufacturers, distributors, pharmacies and patients.

The government's action follows continuing concerns about the affordability of cancer treatment and the difference between medicine procurement prices and the amounts charged to consumers. The issue has also received attention in public discussions about access to life-saving treatment.

How patients can check the new prices

Patients and caregivers should verify the revised MRP before purchasing medicines after November 9. The NPPA has published revised price information for the covered anti-cancer drugs on its official website. The government has also advised consumers to use the Pharma Sahi Daam mobile application to check medicine prices.

Patients should compare the exact brand, strength, dosage form and pack size prescribed by their oncologist. Medicines with similar names may have different strengths or formulations, and the revised price of one product should not automatically be applied to another.

If a pharmacy charges more than the applicable revised MRP, consumers can seek clarification and refer to the official NPPA price list. Keeping the prescription and purchase bill can help patients document any pricing dispute.

A step towards more affordable cancer care

The price-control decision could provide meaningful financial relief, particularly to families who spend a substantial portion of their income on long-term treatment. Lower medicine prices may also help patients continue prescribed treatment without facing the same level of financial pressure.

However, medicine prices are only one part of the overall cost of cancer care. Hospital charges, surgery, chemotherapy administration, radiation therapy, diagnostic tests, travel and follow-up treatment can also place a heavy burden on households. The impact of the new rules will therefore depend not only on lower MRPs but also on effective implementation and transparent billing across pharmacies and hospitals.

The government has presented the estimated Rs 3,357.49 crore saving as an important outcome of the revised pricing exercise. The next test will be whether the new prices are implemented consistently and whether patients can access the listed medicines at the reduced rates.

For patients and caregivers, November 9 will be an important date to check whether the revised prices translate into tangible relief at the pharmacy counter. The policy marks a significant intervention in the pricing of cancer medicines, but its real success will ultimately be measured by how much it reduces the cost of treatment for people who need it.